Top Anti Cancer Imported Medicine Drugs in India - Pharma Five

Pharma Five is a registered firm based in India. We specialize in Named Patient Imports, Imported cancer drugs, Imported medicines in india.

Contact Us Pharma Five Door No. 74, Old No. 26, Fagun Mansion, 3rd Floor, Ethiraj Salai, Egmore, Chennai - 600008 +916374297988 info@pharmafive.org
Buy Talzenna (Talazoparib) Medicine in India

Talzenna (Talazoparib)

Medicine name : Talzenna

Generic name : Talazoparib

Manufactured By : Pfizer Inc.

Indications : Treatment of adults with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene mutations, in combination with enzalutamide.

Medicine Description : A targeted combination therapy for adults with metastatic prostate cancer carrying homologous recombination repair (HRR) gene mutations. Talzenna (Talazoparib) combined with enzalutamide works by inhibiting PARP enzymes and blocking androgen receptor signalling, helping slow cancer cell growth and progression.

Product Introduction

Talzenna (Talazoparib) is an anticancer medicine used in combination with enzalutamide to treat adults with metastatic prostate cancer involving homologous recombination repair (HRR) gene mutations. Its approved indications include metastatic androgen pathway modulation-naïve or -sensitive prostate cancer, as well as metastatic androgen pathway modulation-resistant prostate cancer. Patient eligibility is determined through an FDA-authorised genetic test.

Talazoparib belongs to a class of medicines called poly (ADP-ribose) polymerase (PARP) inhibitors. It works by blocking PARP enzymes involved in DNA repair, making it harder for cancer cells with certain DNA repair gene mutations to survive. Enzalutamide works by blocking androgen receptor signalling, which helps slow prostate cancer growth.

Common side effects may include anaemia, fatigue, nausea, decreased appetite, low platelet counts, low white blood cell counts and dizziness. Serious risks include bone marrow suppression, myelodysplastic syndrome, acute myeloid leukaemia and embryo-fetal toxicity. Regular blood tests and medical monitoring are important throughout treatment.

Uses Of Talzenna (Talazoparib)

Treatment of HRR Gene-Mutated Metastatic Prostate Cancer

Benefits Of Talzenna

Used in combination with enzalutamide to treat adults with metastatic prostate cancer who have specific homologous recombination repair (HRR) gene mutations. Treatment eligibility is determined through an approved genetic test.

Side Effects Of Talzenna (Talazoparib)

Some patients may experience side effects while taking Talzenna (Talazoparib) in combination with enzalutamide. The severity may vary depending on individual health and treatment response.

Common Side Effects of Talzenna (Talazoparib)

  • Anaemia (low red blood cell count)
  • Decreased white blood cell count
  • Decreased platelet count
  • Fatigue
  • Decreased appetite
  • Nausea
  • Back pain
  • Dizziness
  • Constipation
  • Changes in taste
How To Use Talzenna

Talzenna is taken orally as capsules, usually once daily, with or without food. When used with enzalutamide for metastatic prostate cancer, the recommended talazoparib dose is generally 0.5 mg once daily, while enzalutamide is taken at the prescribed dose. Swallow capsules whole and take them at approximately the same time each day. Follow your oncologist's instructions regarding dosage and treatment duration.

How Talzenna (Talazoparib) Works

Talazoparib is a PARP inhibitor that blocks enzymes responsible for repairing damaged DNA. In cancer cells with HRR gene mutations, this further disrupts DNA repair and can lead to cancer cell death. Enzalutamide blocks androgen receptor signalling, reducing the hormonal signals that help prostate cancer cells grow.

Storage Conditions
  • Store Talzenna capsules at 20°C to 25°C (68°F to 77°F).
  • Temporary temperature excursions between 15°C and 30°C (59°F to 86°F) are permitted.
  • Keep the capsules in their original packaging to protect them from damage and contamination.
  • Keep the medicine tightly closed and out of reach of children.
Safety Advice

AlcoholAlcohol CONSULT YOUR DOCTOR

Consult your doctor before consuming alcohol during treatment. Avoid excessive alcohol, especially if you experience fatigue, dizziness or nausea.

PregnancyPregnancy CONSULT YOUR DOCTOR

Talzenna may cause harm to an unborn baby. Women who can become pregnant should use effective contraception during treatment and for 7 months after the last dose. Men with partners who can become pregnant should use contraception during treatment and for 4 months after the last dose.

BreastfeedingBreastfeeding CONSULT YOUR DOCTOR

Breastfeeding is not recommended during treatment and for 1 month after the last dose due to the potential risk of serious adverse effects in the infant.

DrivingDriving CONSULT YOUR DOCTOR

Talzenna may cause fatigue or dizziness. Avoid driving or operating machinery if these symptoms affect your alertness.

KidneyKidney CAUTION

Inform your doctor about existing kidney problems. Patients with moderate or severe kidney impairment may require dose adjustments and closer monitoring.

LiverLiver CAUTION

Inform your doctor about any existing liver disease. Regular medical monitoring may be recommended to assess your overall health and treatment tolerance.

Quick Tips
  • Take Talzenna once daily as prescribed by your oncologist.
  • Swallow capsules whole without crushing, opening or chewing them.
  • Take enzalutamide according to the prescribed treatment schedule.
  • Attend regular blood tests to monitor blood cell counts and treatment effects.
  • Report fever, unusual bleeding, severe fatigue or signs of infection promptly.
  • Read More About - Talzenna (Talazoparib) from Pharma Five.
About Pharma Five

Pharma Five assists patients seeking Talzenna (with Enzalutamide) by facilitating the import of limited quantities for personal medical use, subject to applicable regulations. Depending on the requirements, Form 12A, a valid prescription from a Registered Medical Practitioner (RMP) and other supporting documents may be required.

With more than 20 years of pharmaceutical industry experience, Pharma Five provides specialised medicine consultancy and import assistance for patients requiring Talzenna (with Enzalutamide). The team offers guidance on documentation and helps patients navigate the applicable medicine import procedures. Pharma Five provides extensive pharmaceutical service coverage across India, serving patients and healthcare requirements in prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.

References
  1. https://go.drugbank.com/drugs/DB11760
  2. https://www.fda.gov/drugs/cancer-approvals/fda-approves-talazoparib-enzalutamide-metastatic-androgen-pathway-modulation-naive-or-sensitive
  3. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f2423edd-6d24-495c-aec1-c2f457f08d9a
Faq

General Question

Talzenna (Talazoparib) is an anticancer medicine used in combination with enzalutamide to treat adults with metastatic prostate cancer carrying specific homologous recombination repair (HRR) gene mutations.

Talzenna blocks PARP enzymes involved in DNA repair. This causes further DNA damage in cancer cells with HRR gene mutations, making it difficult for them to survive. Enzalutamide blocks androgen receptor signalling, helping slow cancer growth.

Talzenna with enzalutamide is prescribed for eligible adults with HRR gene-mutated metastatic prostate cancer. Genetic testing is used to identify suitable patients, and a specialist determines whether the treatment is appropriate.

Talzenna is taken orally as capsules, usually at a recommended dose of 0.5 mg once daily when combined with enzalutamide. Swallow the capsules whole with or without food. Follow your oncologist's instructions for both medicines.

Common side effects include anaemia, decreased white blood cell counts, decreased platelet counts, fatigue, nausea, decreased appetite, back pain, dizziness and changes in taste.

Yes. Talzenna can cause serious bone marrow suppression, increasing the risk of anaemia, infections and bleeding. Rare complications include myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). Contact your doctor if you develop fever, unusual bleeding or severe weakness.

Treatment generally continues until the cancer progresses or unacceptable side effects develop. Your oncologist will regularly assess your response and determine whether treatment should continue.

Consult your doctor before consuming alcohol during treatment. Avoid excessive alcohol, particularly if you experience dizziness, nausea or fatigue.

Talzenna can cause fetal harm. Women who can become pregnant should use effective contraception during treatment and for 7 months after the last dose. Men with female partners who can become pregnant should use effective contraception during treatment and for 4 months after the last dose.

Inform your doctor about all prescription medicines, over-the-counter products, vitamins and supplements you take. Certain medicines, including some P-glycoprotein inhibitors, may increase Talzenna exposure and require medical review or dose adjustment.

If you miss a dose or vomit after taking Talzenna, take your next prescribed dose at the usual scheduled time. Do not take an additional dose to make up for the missed one.

Yes. Talzenna can be taken with or without food. Swallow the capsules whole and do not open, crush or dissolve them.

Attend regular blood tests to monitor blood cell counts. Inform your doctor about kidney problems, other medicines and any history of blood disorders. Report fever, unusual bruising, bleeding or persistent weakness promptly.

Store Talzenna capsules at 20°C to 25°C (68°F to 77°F). Permitted temperature excursions are between 15°C and 30°C (59°F and 86°F). Follow the storage instructions on the original packaging.

Pharma Five provides medicine consultancy and import assistance for patients seeking Talzenna (with Enzalutamide). Personal-use medicine imports are subject to applicable regulations, prescriptions and supporting documentation. Pharma Five assists in its procurement.

Timely Service
Doorstep Delivery
Hassle-Free Process
100% Genuine Sources